Blog

Erika Hamilton’s insights into the future of ADCs in oncology – Sarah Cannon Research Institute

Photo taken from Erika Hamilton/X

Jun 24, 2024, 13:33

Erika Hamilton’s insights into the future of ADCs in oncology – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared the following post on LinkedIn:

“We are thrilled to share the latest advancements in cancer research from our experts at Sarah Cannon Research Institute, presented at the 2024 Annual ASCO Meeting. Erika Hamilton, MD’s insights into the future of antibody-drug conjugates (ADCs) highlight exciting new possibilities in oncology. Discover more about these therapies here.”

Source: Sarah Cannon Research Institute/LinkedIn
.

2024 Annual ASCO Meeting ADCs Antibody drug conjugates ASCO 2024 ASCO Annual Meeting cancer cancer innovations Cancer research cancer therapies cancer treatment Erika Hamilton future of oncology OncoDaily Oncology oncology advancements oncology research Research Sarah Cannon Research Institute

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology